Nicholas W. Baxter - 26 Apr 2024 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Director
Signature
/Nicholas Baxter/
Issuer symbol
LEXX
Transactions as of
26 Apr 2024
Net transactions value
$0
Form type
4
Filing time
10 May 2024, 17:11:58 UTC
Previous filing
25 Jul 2023
Next filing
30 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LEXX common shares 11,000 26 Apr 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LEXX Stock Options Award $0 +5,000 +14% $0.000000 40,000 26 Apr 2024 Common Shares 5,000 $2.36 Direct
holding LEXX Stock Options 1,500 26 Apr 2024 Common Shares 1,500 $3.00 Direct F1
holding LEXX Stock Options 6,500 26 Apr 2024 Common Shares 5,000 $3.00 Direct F2
holding LEXX Stock Options 8,400 26 Apr 2024 Common Shares 1,900 $3.00 Direct F3
holding LEXX Stock Options 11,800 26 Apr 2024 Common Shares 3,400 $3.39 Direct
holding LEXX Stock Options 30,000 26 Apr 2024 Common Shares 18,200 $1.96 Direct
holding LEXX Stock Options 35,000 26 Apr 2024 Common Shares 5,000 $0.8700 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $5.31 pursuant to shareholder approval received May 9, 2023
F2 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
F3 Repriced from $6.23 pursuant to shareholder approval received May 9, 2023